NCT04965337View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 11, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Healthy
Interventions
DRUG

ASC42

ASC42 tablet administered orally

DRUG

Placebo

Matching placebo administered orally

Trial Locations (1)

410008

Xiangya Boai Rehabilitation Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY